The use of flavonoids such as oroxylin A can effectively reverse IM resistance in CML within the bone marrow microenvironment by enhancing the sensitivity of CML cells to IM therapy through the regulation of the CXCL12/CXCR7 pathway. This evidence concerns the gene CXCL12 and chronic myelogenous leukemia, BCR-ABL1 positive.